Zejula approved for certain female cancers

March 28, 2017

(HealthDay)—Zejula (niraparib) has been approved by the U.S. Food and Drug Administration to treat adult women with recurring cancers of the ovaries, fallopian tubes or abdominal wall (peritoneum) whose tumors have shrunk in response to platinum-based chemotherapy.

Citing the National Cancer Institute, the FDA said in a news release that more than 22,000 women are expected to be diagnosed with these cancers this year, and more than 14,000 will die of these diseases.

Zejula is designed to block an enzyme involved in repairing damaged DNA. The thought is that by blocking this enzyme, cancer cells would die and slow down or stop tumor growth, the FDA said.

The drug was evaluated in clinical studies involving 553 people with any of these recurring cancers who had had their tumors shrunk by at least two doses of . The average progression-free survival of certain women given Zejula was 21 months, compared with 5.5 months among women who took a placebo, the FDA said.

The most common side effects were low levels of , or blood platelets; heart palpitations, nausea, constipation, abdominal pain, and mucous membrane inflammation.

More serious adverse reactions could include high blood pressure and bone marrow problems, the FDA said.

Approval of Zejula was granted to Tesaro Inc.

Explore further: FDA clears ovarian cancer drug for hard-to-treat disease

More information: Visit the FDA to learn more.

Related Stories

New treatment approved for soft-tissue cancers

October 19, 2016

(HealthDay)—Lartruvo (olaratumab) has been approved by the U.S. Food and Drug Administration to treat adults with certain soft-tissue sarcomas, cancers that develop in areas such as the muscles, fat, blood vessels and tendons.

Bavencio approved for rare skin cancer

March 23, 2017

(HealthDay)—Bavencio (avelumab) has been approved by the U.S. Food and Drug Administration to treat a rare but aggressive form of skin cancer called Merkel cell carcinoma (MCC), the agency said Thursday in a news release.

Lonsurf approved for advanced colon cancer

September 23, 2015

(HealthDay)—The combination pill Lonsurf (trifluridine and tipiracil) has been approved by the U.S. Food and Drug Administration to treat advanced colon cancer for people who aren't responding to other treatments, the agency ...

Xermelo approved for tumor-related diarrhea

March 1, 2017

(HealthDay)—Xermelo (telotristat ethyl) tablets have been approved by the U.S. Food and Drug Administration to treat adults with carcinoid syndrome diarrhea, one of a collection of symptoms related to rare carcinoid tumors.

New drug approved for lack of certain white blood cells

August 30, 2012

(HealthDay)—The U.S. Food and Drug Administration has approved the drug tbo-filgrastim to treat certain cancer patients undergoing chemotherapy who have a condition called severe neutropenia, the FDA said in a news release.

Recommended for you

Blocking cancer—scientists find new way to combat disease

June 21, 2017

New findings published in Nature Chemical Biology show promise for finding new solutions to treat lung cancer and other deadly diseases. Kentucky continues to lead the nation in incidence and death rates from lung cancer, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.